Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financi...(ue 75 -- ...)

Date:8/5/2009

ue 75 -- 75 -- TOTAL REVENUE 18,364 389 21,694 588 OPERATING EXPENSES: Cost of services -- 14 -- 14 Research and development: Non-cash compensation 361 251 562 (729) Other research and development 1,456 4,242 2,830 35,069 Total research and development 1,817 4,493 3,392 34,340 Selling, general and administrative: Non-cash compensation 1,028 1,767 1,398 3,484 Other selling, general and administrative 1,528 2,078 2,569 3,965 Total selling, general and administrative 2,556 3,845 3,967 7,449 TOTAL OPERATING EXPENSES 4,373 8,352 7,359 41,803 OPERATING INCOME (LOSS) 13,991 (7,963) 14,335 (41,215) OTHER INCOME (EXPENSE): Interest and other income (expense), net 141 274 248 (929) INCOME (LOSS) FROM CONTINUING OPERATIONS 14,132 (7,689) 14,583 (42,144) Loss from discontinued operations -- (8) -- (89) NET INCOME (LOSS) $ 14,132 $ (7,697) $ 14,583 $ (42,233) NET INCOME (LOSS)PER COMMON SHARE Basic $ 0.30 $ (0.17) $ 0.30 $ (0.96) Diluted $ 0.29 $ (0.17) $ 0.30 $ (0.96) SHARES USED IN COMPUTING NET LOSS PER COMMON SHARE Basic 47,855,425 44,095,873 47,854,664 43,906,974 Diluted 48,189,552 44,095,873 48,149,600 43,906,974 Balance Sheet Information: June 30,
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint